Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Blogs Comment On Senate Resolution On Antiabortion Violence, Role Of Midwives In Health Reform, Other Topics
The following summarizes selected women"s health-related blog entries.~ ""Anonymous" Republican Senator Obstructs Resolution To Condemn Clinic Violence," Jodi Jacobson, RH Reality Check: On Thursday, an unnamed Republican senator "used his power to put a "hold"" on a resolution (S.R. 187) "condemning violence against women"s health providers, thereby blocking any vote on the resolution," Jacobson writes. She adds, "So much for agreeing on at least a basic premise in the debate about choice, reproductive rights or even reproductive health." Such holds, which senators can submit anonymously and without explanation, allow Republicans to "get away with sorrowful expressions to the media on violence" without having "to be put to the test of actually voting to denounce the violence against" abortion providers like George Tiller, Jacobson writes. Sens. Jeanne Shaheen (D-N.H.), Barbara Boxer (D-Calif.) and Amy Klobuchar (D-Minn.), who introduced the resolution, "intended [it] to be non-controversial," but the "condemnation of violence is apparently too much for some Republicans to bear," Jacobson continues. She adds that the House unanimously passed a resolution (H.R. 505) last week condemning violence in places of worship. The three senators who introduced the Senate resolution "decided to move forward with their resolution" without the House"s language because they "feel condemning violence against women"s health care providers and agreeing not to use violence as a means of resolving differences are not objectionable viewpoints," Jacobson writes. She concludes, "Apparently, there is no common ground in the Senate on not using violence where women"s health is concerned" (Jacobson, RH Reality Check, 6/19).~ "Supporting MAMAs," Amie Newman, RH Reality Check: Under President Obama, who is calling for "an exploration of common ground in the abortion debate and is spearheading the fight for health care reform, we have an opportunity to re-examine the gamut of women"s reproductive and sexual health care in order to improve access to all care," Newman writes. She continues that the Midwives and Mothers in Action campaign, a collaboration of advocacy and consumer groups, is working "to ensure that health care reform remembers midwifery." The group is lobbying for federal recognition of certified professional midwives as a means to increase women"s access to affordable, quality obstetrical care and working to ensure that "Medicaid coverage for certified professional midwives is included in any health care reform," Newman writes. According to Newman, in 25 states "it is illegal to choose the care provider or setting for your birth because certified professional midwives are outlawed as birth facilitators." She continues, "As we work towards immense health care reform, the question for all reproductive health advocates should be: How much longer will we tolerate a system in which women"s and babies" health and lives are compromised, costs to the consumer are rising, access to childbirth care remains inequitable and certified professional midwives must fight for their livelihood?" Newman concludes, "Access to abortion care, contraception and childbirth care should be seen as concentric circles -- they are all connected and all part of the continuum of [women"s] reproductive and sexual health care with which reproductive [health] and rights advocates should be concerned" (Newman, RH Reality Check, 6/22).~ "Roe Protects Pregnant Women, Too," Rachel Roth, RH Reality Check: "Roe v. Wade stands for women"s reproductive self-determination: for the right to have an abortion and the right to have a baby," Roth writes. She adds, "Both dimensions of Roe"s promise are critical to women"s lives, yet most people are far more familiar with one than the other." Roth continues that although most people know that Roe "recognized women"s constitutional right to an abortion," those rights "are not absolute." According to Roth, "Roe did not establish a contest between women"s rights and "feta
new payday loan lenders
ASGS Issues Position Statement Supporting TIF Natural Orifice Surgery For GERD
EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), announced that the American Society of General Surgeons (ASGS) has published a position statement endorsing its Transoral Incisionless Fundoplication (TIF) procedure for the treatment of GERD. ASGS is the preeminent society of general surgeons with membership exceeding 2,000.
News of the day
American Indian Tribes To Get $500M In Stimulus Funds For Health Projects
Newly appointed IHS Director Yvette Roubideaux on Friday announced that American Indian tribes will receive $500 million as part of the $787 billion economic stimulus package to fund health care projects, the Green Bay Press-Gazette reports. According to the Press-Gazette, American Indian tribes frequently cite lack of adequate health care as a major issue on reservations. President Obama also included a $454 million increase for IHS programs in his 2010 budget proposal to address such barriers.The $500 million includes:
Oncology

Study Results Present Efficacy And Safety Findings From The PHIRST-1 Study Of Patients With Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved exercise capacity and improved time to clinical worsening in patients with pulmonary arterial hypertension (PAH)(1). The randomized, double-blind, 16-week, placebo-controlled Phase 3 study followed 405 patients with PAH, either treatment-naive or taking bosentan, randomized to placebo or tadalafil 2.5 mg, 10 mg, 20 mg or 40 mg orally. Results from the study entitled, "Tadalafil Therapy for Pulmonary Arterial Hypertension," were published in today"s issue of Circulation. The study formed the basis of the United States Food and Drug Administration (FDA) approval to market tadalafil tablets for the treatment of PAH under the brand name ADCIRCA(TM). "PAH is a rare, life-threatening disease," said lead investigator Dr. Nazzareno Galie, Associate Professor of Cardiology at the University of Bologna and head of the Pulmonary Hypertension Centre at the Institute of Cardiology. "The results of this study are encouraging for PAH clinicians and the patients they treat." About the Study The randomized, double-blind, 16-week, placebo-controlled Phase 3 study monitored 405 patients with idiopathic PAH or PAH associated with anorexigen use, connective tissue disease, human immunodeficiency virus (HIV) infection, or congenital systemic-to-pulmonary shunts. Patients were randomized in groups and received one of five treatments, tadalafil 2.5 mg, 10 mg, 20 mg, 40 mg or placebo, orally once a day as monotherapy or as add-on therapy to bosentan. The primary endpoint was change from baseline to Week 16 in six-minute walk distance (6MWD)(2). Demographics, clinical data and health-related quality of life data were collected at baseline. Clinical and health-related quality of life data were collected again at weeks eight and sixteen(3). Tadalafil increased 6MWD in a dose-dependent manner, only the 40 mg dose met the pre-specified level of statistical significance of less than 0.01 (pAbout ADCIRCA ADCIRCA is a prescription medicine used to treat PAH, a life-threatening disease that constricts the flow of blood through the pulmonary vasculature. United Therapeutics Corporation licensed the rights to develop, market, promote and commercialize ADCIRCA for pulmonary hypertension in the United States and Puerto Rico from Eli Lilly & Company in November 2008. ADCIRCA contains the same active ingredient as CIALIS(R) (tadalafil), which is marketed by Eli Lilly & Company to treat erectile dysfunction (impotence) in more than 100 countries. Important Safety Information for ADCIRCA ADCIRCA should not be used in patients taking medicines that contain nitrates (often used for chest pain) as the combination could cause a sudden, unsafe drop in blood pressure. If a patient experiences anginal chest pain after taking ADCIRCA they should seek immediate medical attention. Patients with a known serious hypersensitivity to tadalafil (ADCIRCA or CIALIS) should not take ADCIRCA. PDE5 inhibitors, including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, physicians should carefully consider whether their patients with underlying cardiovascular disease could be adversely affected by such effects. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended. Patients should discuss their medical condition and all medications with their physician before starting ADCIRCA. The use of ADCIRCA with alpha blockers, blood pressure medications, and alcohol may cause a lowering of blood pressure. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, dosage adjustments are required. Certain populations of PAH patients such as those with mild-to-moderate renal or hepatic impairment or those taking the drug ritonavir should use a dose of 20 mg daily when beginning therapy with ADCIRCA. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided. The safety and efficacy of combinations of ADCIRCA with CIALIS or other PDE5 inhibitors have not been studied. Therefore, the use of such combinations is not recommended. The most common side effects with ADCIRCA seen in the PHIRST-1 clinical trial were headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia and nasal congestion. In rare instances, patients taking PDE5 inhibitors (including tadalafil) reported a sudden decrease or loss of vision or hearing, or in men, an erection lasting more than four hours. A patient who experiences a decrease or loss in vision or hearing or prolonged erection should seek immediate medical attention. About United Therapeutics Corporation United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. About Eli Lilly and Company Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world"s most urgent medical needs. References (1) Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 3. (2) Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 6. (3)Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 6. (4)Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 10. (5)Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 31, Table 2. (6) Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 10. (7)Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 11. (8)Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 31, Table 2. (9) Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 32, Table 2. (10) Galie, N., et al. "Tadalafil therapy for pulmonary arterial hypertension" manuscript. Registration Trial Number: NCT00125918. Page 11. United Therapeutics Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009